Trial Profile
Randomized phase-II trial of abiraterone acetate plus LHRH-therapy versus abiraterone acetate sparing LHRH-therapy in patients with progressive chemotherapy-naive castration-resistant prostate cancer (SPARE)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms SPARE
- 19 Jul 2019 This trial has been completed in Germany
- 12 Jul 2014 New trial record